logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Anjarium Biosciences Raises Chf 55.5M ($61M) Series A Financing To Develop Next-Generation Non-Viral Gene Therapies

Sep 16, 2021•over 4 years ago

Round Type

series a

Zurich

Description

Anjarium Biosciences AG ("Anjarium"), a biotech company focused on creating and delivering a new class of non-viral gene therapies today announced the closing of a CHF55.5M ($61M) Series A financing. The round was co-led by Abingworth and Gimv, with significant participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).

Company Information

Company

Anjarium Biosciences

Location

Zurich, Zurich, Switzerland

About

Anjarium is focused on creating a new class of non-viral gene therapies to deliver more predictable, enduring, and inclusionary ways to tackle genetic disease throughout a patient's lifetime. The Company's versatile platform aims to leverage breakthrough science and expertise at the interface of genetic medicine, synthetic biology and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Investors in Anjarium include leading international and strategic investors Abingworth, Gimv, Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company). www.anjarium.com